Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy for Patients with Refractory Irritable Bowel Syndrome

Leonard B. Weinstock¹, Victoria S. Jasion²

¹Specialists in Gastroenterology, St. Louis, USA.
²Department of Medical Affairs, Entera Health, Inc., Cary, USA.

DOI: 10.4236/ojgas.2014.410047                

Abstract

Background: A small double-blind study showed benefits of serum-derived bovine immunoglobulin/protein isolate (SBI), for diarrhea-predominant irritable bowel syndrome (IBS-D) [1]. The purpose of this chart review was to assess safety and clinical outcomes of SBI in refractory irritable bowel syndrome (IBS) patients. Methods: A retrospective review of 35 IBS patients with diarrhea or mixed diarrhea/constipation pattern (IBS-M) who were administered SBI 5 grams twice daily was performed. Clinical response (“good response” or “no response”) and adverse events were determined by follow-up after four weeks of therapy. Patients were included for evaluation if a lactulose breath test (LBT) had been performed prior to SBI. All patients were refractory to common IBS therapies. The response rate to the inclusion of SBI was calculated in three separate groups: dividing patients based on their LBT results (positive or negative), dividing patients by their IBS diagnosis (IBS-D or IBS-M) and grouping all patients together. Results: Analysis was carried out on 26 IBS-D/-M patients with LBT results. Two patients were lost to follow-up and were excluded from data analysis. The positive LBT group (N = 11) had a 73% (p = 0.117) positive response rate to SBI. The negative LBT group (N = 13) had a significant response rate of 77% (p = 0.040). If patients were divided by IBS diagnosis or grouped together, the response rate to SBI was similarly ranging from 69% - 88%. Adverse events leading to cessation of SBI occurred in 3 of 24 patients. Conclusion: SBI appeared to be a safe and effective nutritional moiety in refractory IBS-D and IBS-M patients. Larger, double-blind studies are needed.

Keywords

Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth (SIBO), Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI)

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Wilson, D., Evans, M., Weaver, E., Shaw, A.L. and Klein, G.L. (2013) Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome. Clinical Medicine Insights: Gastroenterology, 6, 49-60. http://dx.doi.org/10.4137/CGast.S13200
[2]	Saito, Y.A., Schoenfeld, P. and Locke, G.R. (2002) The Epidemiology of Irritable Bowel Syndrome in North America: A Systematic Review. The American Journal of Gastroenterology, 97, 1910-1915. http://dx.doi.org/10.1016/S0002-9270(02)04270-3
[3]	Ringel, Y. and Drossman, D.A. (2000) Toward a Positive and Comprehensive Diagnosis of Irritable Bowel Syndrome. Medscape General Medicine 2.
[4]	Collins, S.M. (2014) A Role for the Gut Microbiota in IBS. Nature Reviews Gastroenterology & Hepatology, 11, 497-505. http://dx.doi.org/10.1038/nrgastro.2014.40
[5]	Simren, M., Barbara, G., Flint, H.J., Spiegel, B.M., Spiller, R.C., Vanner, S., Verdu, E.F., Whorwell, P.J., Zoetendal, E.G. and Rome Foundation, C. (2013) Intestinal Microbiota in Functional Bowel Disorders: A Rome Foundation Report. Gut, 62, 159-176. http://dx.doi.org/10.1136/gutjnl-2012-302167
[6]	Enck, P., Junne, F., Klosterhalfen, S., Zipfel, S. and Martens, U. (2010) Therapy Options in Irritable Bowel Syndrome. European Journal of Gastroenterology & Hepatology, 22, 1402-1411. http://dx.doi.org/10.1097/MEG.0b013e3283405a17
[7]	Pimentel, M. (2010) An Evidence-Based Treatment Algorithm for IBS Based on a Bacterial/SIBO Hypothesis: Part 2. The American Journal of Gastroenterology, 105, 1227-1230. http://dx.doi.org/10.1038/ajg.2010.125
[8]	Petschow, B.W., Burnett, B., Shaw, A.L., Weaver, E.M. and Klein, G. L. (2014) Serum-Derived Bovine Immunoglobulin/Protein Isolate: Postulated Mechanism of Action for Management of Enteropathy. Clinical and Experimental Gastroenterology, 7, 181-190. http://dx.doi.org/10.2147/CEG.S62823
[9]	Martinez, C., Lobo, B., Pigrau, M., Ramos, L., Gonzalez-Castro, A.M., Alonso, C., Guilarte, M., Guila, M., de Torres, I., Azpiroz, F., Santos, J. and Vicario, M. (2013) Diarrhoea-Predominant Irritable Bowel Syndrome: An Organic Disorder with Structural Abnormalities in the Jejunal Epithelial Barrier. Gut, 62, 1160-1168. http://dx.doi.org/10.1136/gutjnl-2012-302093
[10]	Thompson, W.G., Longstreth, G.F., Drossman, D.A., Heaton, K.W., Irvine, E.J. and Muller-Lissner, S.A. (1999) Functional Bowel Disorders and Functional Abdominal Pain. Gut, 45, II43-II47. http://dx.doi.org/10.1136/gut.45.2008.ii43
[11]	Walonick, D.S. (1996-2014) StatPac Statistics Calculator.
[12]	Petschow, B.W., Burnett, B.P., Shaw, A.L., Weaver, E.M. and Klein, G.L. (2014) Dietary Requirement for Serum-Derived Bovine Immunoglobulins in the Clinical Management of Patients with Enteropathy. Digestive Diseases and Sciences, in press. http://dx.doi.org/10.1007/s10620-014-3322-0
[13]	Bosi, P., Casini, L., Finamore, A., Cremokolini, C., Merialdi, G., Trevisi, P., Nobili, F. and Mengheri, E. (2004) Spray-Dried Plasma Improves Growth Performance and Reduces Inflammatory Status of Weaned Pigs Challenged with Enterotoxigenic Escherichia Coli K88. Journal of Animal Science, 82, 1764-1772.
[14]	Asmuth, D.M., Strombaugh, J., Ursell, L., Ma, Z.M., Albanese, A., Hodzic, E., Troia-Canico, P., Flynn, N.M., Yotter, T., Miller, C.J. and Knight, R. (2013) Changes in Stool Microbiota, Bacterial Translocation and Mucosal Immunity after Oral Serum-Derived Bovine Immunoglobulin (SBI) Administration. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlanta, 3-6 March 2013.
[15]	Henderson, A.L., Horgan, A., Detzel, C.J., Maas, K.J. and Weaver, E. (2014) Serum-Derived Bovine Immunoglobulin/Protein Isolate Binds and Neutralizes Clostridium Difficile Toxins A and B. Digestive Disease Week (DDW), Chicago, 3-6 May 2014.